Overview

Active Pharmaceutical Ingredient (API) Market is estimated to register a CAGR of over 5.8% during the forecast period 2022 to 2028.

An abundance of capital is needed for the production of API, as the procedures require very systematic and precise protocols. As a result, there is no focus on physical manpower and setting up of costly manufacturing units. By adopting tactful and strategic outsourcing, the companies can emphasize more on their competencies, thereby, culminating in heightened productivity.

Active pharmaceutical ingredients (APIs) which have good quality, are crucial for the production of safe and effective medicines. However, it should be noted that not all pharmaceutical companies have adopted their own individual API manufacturing units. According to the market analysis, the rise of ailments such as cardiovascular and periodontal diseases, back pain, cancer and dental caries are factors which are expected to propel the active pharmaceutical ingredient market growth. The need for affordable medication and the rise in the volume of ANDA filings is projected to augment the market.

The acceptance of biologics and biosimilars and the rise in ailments such as cancer and chronic diseases, are factors which have been predicted to drive the market. However, aspects such as strict regulatory bodies and intense competition among other players, coupled with issues relating to price control regulations are all likely to pose potential threats to the market growth.

Some major global players in the APIs market include Pfizer, Inc., Novartis International AG, Sanofi, Boehringer Ingelheim, Bristol-Myers Squibb, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, GlaxoSmithKline plc, Merck & Co., Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., AstraZeneca, Cipla, Inc., Mylan N.V., Dr. Reddy’s Laboratories Ltd, Sun Pharmaceutical Industries Ltd., API Pharma Tech, BDR Pharmaceuticals Internationals Pvt. Ltd., Sreepathi Pharmaceuticals Limited, Shilpa Medicare Limited, Albemarle Corporation, Viatris Inc., Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., Biocon

Active Pharmaceutical Ingredient (API) Market Segmentation:

By Drug Type
• Prescription Drugs
• Over-the-counter Drugs

By Manufacturer
• Captive (In-House) Manufacturer
• Merchant (Contract) Manufacturer

By Therapeutic Application
• Communicable Diseases
• Oncology
• Diabetes
• Cardiovascular Disease
• Pain management
• Respiratory Diseases
• Other Therapeutic Applications

By End-User
• Pharmaceutical & Biotechnology Industry
• Contract Research Organizations
• Contract Manufacturing Organizations
• Other End-User

By Synthesis
• Synthetic
o Type
• Innovative Synthetic API
• Generic Synthetic API
• Biotech
o Type
• Innovative Synthetic API
• Generic Synthetic API
o Product
• Monoclonal Antibodies
• Hormones
• Cytokines
• Recombinant Proteins
• Therapeutic Enzymes
• Vaccines
• Blood Factors
o Expression System
• Mammalian Expression Systems
• Microbial Expression Systems
• Yeast Expression Systems
• Insect Expression Systems
• Other Expression Systems

By Region

North America
Europe
Asia- Pacific
Latin America
Middle East and Africa

Competitive Landscape:

• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:

Growth prospects
SWOT analysis
Key trends
Key data-points affecting market growth

Objectives of the Study:

To provide with an exhaustive analysis on the active pharmaceuticals market by drug type, by manufacturer, by therapeutic application, by end-user, by synthesis and by region
To cater comprehensive information on factors impacting market growth (drivers, restraints, industry-specific restraints and opportunities)
To forecast and evaluate micro-markets and the overall market
To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
To record, evaluate and analyse competitive landscape mapping- technological advancements, product launches, expansions and mergers

Flexible Delivery Model:

We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
The customization Mobility Care offered are free of charge with purchase of any license of the report
You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com